OX2R agonists such as Danavorexton [44], Firazorexton [45], SB-668875 [46], Suntinorexton [47], TAK-861, and TAK-994 [48] may provide a more targeted approach for the chronic sleep disorders seen in our patient cohort; however, they are poorly understood but have indications in narcolepsy, sleep architecture in old age, anesthesia emergence, opioid-induced sedation, respiratory depression, and even anti-tumoral properties and need further investigation regarding their effects on the PTSD population. This evidence concerns the gene HCRTR2 and narcolepsy.